Call 800 665 0411 to learn about our services for your stock

Search   Follow Investorideas on Twitter   Investorideas is on Facebook   Investorideas is on Youtube   Investorideas is on Pinterest  Investorideas is on stocktwits   Investorideas is on tumblr   Investorideas is on LinkedIn   Investorideas Instagram   Investorideas Telegram   Investorideas Gettr   Investorideas RSS

Share on StockTwits

Canadian Veterinary Co. Revenue Increased to CA$12.7 Million in First Half of 2023

Source: Streetwise Reports


September 1, 2023 ( Newswire) Grey Wolf Animal Health Corp. has announced the financial results of the last quarter. Read on to see why one newsletter writer believes this stock is worth looking into.

Grey Wolf Animal Health Corp. (WOLF.TSXV) has announced the financial results from the quarter and six months that ended on June 30, 2023. The highlights of these results included that the company's revenue increased by 8.8% to CA$6.7 million since last year, and revenue increased by 12.6% to CA$12.7 million for the first half of 2023.

Other highlights include that the company's gross profits increased by 5.5% to CA$3.4 million for Q2 of 2023 and increased again by 12.9% to CA$6.5 million for the first half of 2023. The adjusted before-tax earnings was CA$1 million for the quarter compared to CA$1.1 million for the same period in 2022 and CA$2.0 million for the first half of the year. This is a significant increase from last year, which saw CA$2.0 million for the entire year.

According to Angela Cechetto, CEO of Grey Wolf, "The second quarter of 2022 was a continuation of what we experienced in the first quarter. We saw revenue grow by 8.8% to CA$6.7 million, driven by organic growth within our product portfolio as well as new products launched in 2022. Gross margins have remained consistent with previous quarters due to the product mix sold in our Animal Health and Pharmacy businesses during the first six months of 2023. In addition, even as we absorb the additional costs associated with operating a public entity, our Adjusted EBITDA1 has remained steady."

Trending Up

The animal health industry in the United States was valued at US$11.92 billion in 2022 and is expected to grow by 8.7% before 2030. Pet supplies are also a relatively recession-proof market due to the humanization of pets and their integration into family units, as evidenced by growing markets like pet insurance.

As vet offices have been able to return to normal after the pandemic, and as digital services have increased, demand has started to trend upwards.

A Company With Big Achievements

Grey Wolf has a history of launching successful products, including Hide and Treat, a product meant to make administering medication to pets at home more convenient, in 2019. The company was also listed as TSXV:WOLF earlier this year. Grey Wolf reports that it has been cash flow positive since 2021.

Grey Wolf recently launched a couple of new pharmaceutical drugs in the Canadian veterinary market.

According to the company, "SEDAJECT (dexmedetomidine hydrochloride injection, 0.5mg/ml) is a sedative and an analgesic intended for dogs and cats to facilitate clinical examinations, clinical procedures, minor surgical operations, and minor dental operations."

The company also notes that "ATAJECT (atipamezole hydrochloride injection, 5.0mg/ml) is intended to reverse the clinical effects of SEDAJECT in cats and dogs."

Technical Analyst Clive Maund said of the company that it is "worth taking a quick look at Grey Wolf Animal Health Corp here as it looks like a low-risk play at this juncture as its stock appears to be just starting higher out of a base pattern as the company's business and earnings grow."

Maund rated Grey Wolf as a Speculative Buy and not unduly speculative at this juncture. The company's stock broke out from a double-bottom base pattern in June following a bear market. Following the breakout, the price retreated and started higher again in August.

Ownership and Share Structure

According to Reuters, management and insiders own 14.02% of the company.

Ian Sandler owns 10.03% with 3.11 million shares, Shawn Douglas Aspden owns 2.92% with 0.91 million shares, Robert Paul Harris owns 0.75% with 0.23 million shares, and Jill Terilee Angevine owns 0.32% with 0.10 million shares.

As for institutions, Bloom Burton & Co. Inc. owns 11.63% with 3.61 million shares.

There are 31.03 million shares outstanding and 26.68 million free-float traded shares. The company has a market cap of CA$17.14 million. It trades in the 52-week period between CA$0.68 and CA$1.40.

More Info:

Disclaimer/Disclosure: is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investing involves risk and possible losses. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. Contact management and IR of each company directly regarding specific questions.

More disclaimer info: Learn more about publishing your news release and our other news services on the newswire

Global investors must adhere to regulations of each country. Please read privacy policy: - A Leading Global Investor Website for Biotech Industry Stocks - investing ideas in biotechnology stocks, medical technology and life sciences

Like Biotech Stocks? View our Biotech Stocks Directory

Get News Alerts on Biotech Stocks

Buy a biotech guest post on